SEC Filings

SEC Filings

Filing date	Description	Form	View
Aug 01, 2017	Amendment to a previously filed 8-K	8-K/A	View HTML 0001104659-17-048454.pdf 0001104659-17-048454.rtf 0001104659-17-048454.xls
Aug 01, 2017	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001047469-17-004898.pdf 0001047469-17-004898.rtf 0001047469-17-004898.xls
Jul 26, 2017	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-17-046953.pdf 0001104659-17-046953.rtf 0001104659-17-046953.xls
Jul 25, 2017	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-17-046804.pdf 0001104659-17-046804.rtf 0001104659-17-046804.xls
Jul 21, 2017	EFFECT	EFFECT	View HTML 9999999995-17-001884.pdf 9999999995-17-001884.rtf
Jul 18, 2017	Pre-effective amendment to an S-3 filing	S-3/A	View HTML 0001104659-17-045493.pdf 0001104659-17-045493.rtf 0001104659-17-045493.xls
Jul 10, 2017	Amendment to a previously filed 8-K	8-K/A	View HTML 0001104659-17-044258.pdf 0001104659-17-044258.rtf 0001104659-17-044258.xls
Jun 19, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0000904454-17-000446.pdf 0000904454-17-000446.rtf 0000904454-17-000446.xls
Jun 19, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-17-004079.pdf 0001214659-17-004079.rtf 0001214659-17-004079.xls
Jun 16, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-17-004065.pdf 0001214659-17-004065.rtf 0001214659-17-004065.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE